Please login to the form below

Not currently logged in
Email:
Password:

Elan reveals new hires to board

Irish-headquartered Elan has appointed Jonas Frick and Giles Kerr as non-executive directors of the company.

Irish-headquartered Elan has appointed Jonas Frick and Giles Kerr as non-executive directors of the company.

Frick is the former CEO of Scandinavian Life Science Ventures (SLS Ventures), an investment company in the life science sector in Scandinavia.

Before joining SLS Ventures, Frick was the CEO and President of the publicly traded biotech company Medivir. He has also worked in senior executive positions in Pharmacia's international businesses in the CNS and Autoimmune areas across Italy, Sweden and Japan.

Kerr is currently director of finance with the University of Oxford and a fellow of Keble College. He is also director and chairman of the Audit Committee of Victrex and a director of Isis Innovation.

Prior to these roles, he was group finance director and CFO of Amersham, a UK-based medical diagnostics and life science company, whic was acquired by GE Healthcare in 2004.

Kyran McLaughlin, chairman of Elan, said, "We are delighted to welcome Jonas and Giles to our board. Their experience and enthusiasm will add greatly to the overall board and to the company. This represents another important step in developing the board's composition to achieve the appropriate mix of backgrounds and industry experience."

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Onyx Health Ltd

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics